OLIG1 and gastric cancer: The molecular mechanisms of the interaction of CCNDBP1 with these proteins involve G1/S cell cycle phase progression in hepatocytes [13]; tumor suppression in liver cancer [10,14,15,16], breast cancer [15,17,18,19], gastric cancer (GC) [19], lung cancer [20], prostate cancer [19], and colon cancer [5]; regulation of TGF-β target genes, including the Olig1-Smad synexpression group [12]; and regulation of skeletal myogenesis interacting with MyoD [11].